-
Antib Ther: Clinical application potential for CD47-SIRP alpha macrophage immunophhagic immune checkpoint pathway target blocking
Time of Update: 2020-05-29
Recently, Antibody Therapeutics, a journal of the Chinese Antibody Association and published by Oxford University Press, published a review paper entitled "Macrophage checkpoint blockade: a perspec
-
FDA approves AstraZeneca/Merck's PARP inhibitor Lynparza to treat prostate cancer
Time of Update: 2020-05-29
AstraZeneca and Merck announced that the FDA has approved its PARP inhibitor Lynparza (olaparib) for the treatment of patients with homogenous resusandive (HRR) gene mutations, and the progression
-
Aging: Prognosis value of immunoscoring and immune microenvironment-related genes to hepatocellular carcinoma
Time of Update: 2020-05-29
Mastering the characteristics of tumor immune microenvironment is very important to improve the effect of immunotherapy in this study, researchers calculated immune and matrix scores in 371 pati
-
ENHERTU, AN ANTIbody drug conjugated with HER2, has been awarded the FDA's breakthrough therapy title to treat HER2-positive metastatic non-small cell lung cancer
Time of Update: 2020-05-29
AstraZeneca and Daiichi Sankyo's target HER2 antibody drug conjugated ENHERTU (FAM-trastustudeuxtecan-nxki) earned the U.S Food and Drug Administration's (FDA) breakthrough therapy designation (BTD
-
Nat Med: New Progress in Pancreatic Cancer Treatment! Triple therapy of CXCR4 antagonists , PD-1 inhibitors and chemotherapy, with a disease control rate of 77% in the preliminary trial
Time of Update: 2020-05-29
Pancreatic cancer is perhaps the hardest hard bone to chew on in immunotherapy thick extracellular matrix as a protective shell, highly inhibited immune microenvironment, coupled with sly and sop
-
Three magnetic resonance imaging performance of adenosine soft tissue sarcoma
Time of Update: 2020-05-29
Adenospora soft tissue sarcoma (ASPS) is a rare soft tissue malignant tumor that accounts for less than 1% of soft tissue sarcoma The disease is common in young and middle-aged women aged 15 to 35
-
Angewandte Chemie: New probe helps visualize detection of glioma markers
Time of Update: 2020-05-29
Recently, Huang Wei, a member of the Chinese Academy of Sciences, in collaboration with Li Lin, a professor at Nanjing University of Technology, and researchers from the National University of Sing
-
TREATMENT OF NTRK GENE FUSION TUMORS: LAROTRECTINIB TO BE AVAILABLE IN JAPAN
Time of Update: 2020-05-29
Bayer has recently submitted a sales license application for larotrectinib to Japan's Ministry of Health, Labour and Welfare (MHLW) Larotrectinib is an oral TRK inhibitor used to treat late-stage o
-
Lancet Oncol: Quality of Life Assessment Update (QLQ-LC29) for Lung Cancer Patients
Time of Update: 2020-05-29
The European Organization for Cancer Research and Treatment (EORTC) Quality of Life Questionnaire Lung Cancer 13 (QLQ-LC13) assessed the quality of life (QOL) in lung cancer patients and was the fi
-
NAT MED: IL-8 associated with reduced clinical benefit from PD-L1 blocking
Time of Update: 2020-05-29
Although the rise in plasma interleukin-8 (pIL-8) was associated with adverse results in immunocheckpoint blocking therapy, it was not fully evaluated in large randomized studies recently, in pat
-
World's second third-generation EGFR target son-in-a new drug Amatinib to market
Time of Update: 2020-05-29
Ametini listing site to scientific and technological innovation to fill the gap in domestic three generations of EGFR target drug Amatini is the world's second and the first domestic three-ge
-
Int J Cancer: Study reveals EphA2-YAP pathway drives growth of stomach cancer and treatment of drug resistance
Time of Update: 2020-05-29
Yes-related protein (YAP) is a transcription-assisted activator that promotes cell proliferation, stem cell maintenance and tissue balance The activity of YAP is regulated mainly by the Hippo pathw
-
Lancet Oncol?: Atezolizumab in combination with Capoplatinum and nab-paclitaxel for preoperative chemotherapy for non-small cell lung cancer
Time of Update: 2020-05-29
About 25% of non-small cell lung cancer patients have resusible ib-IIA disease, and although perioperative chemotherapy is the standard of treatment, this treatment strategy provides only modest be
-
U.S. approves PD-L1 monoantigen Tecentriq for first-line treatment of non-small cell lung cancer
Time of Update: 2020-05-29
The U.S Food and Drug Administration has approved Roche's PD-L1 monoresistic Tecentriq (atezolizumab) for first-line treatment in adult patients with high PD-L1 expression without EGFR or ALK gene
-
CTM: Large-scale population study that uses line chart strains to predict distant metastasis and overall survival of colorectal cancer patients
Time of Update: 2020-05-29
There were 148,000 new colorectal cancer (CRC) patients in the United States in 2019 alone, of which 146 died every day, the third highest rate of death of any malignant tumor Over the past 30 year
-
Blood: EPOCH Joint vorinostat treatment of HIV-related non-Hodgkin lymphoma
Time of Update: 2020-05-29
EPOCH scheme: etoposide (VP-16) 50mg/m2, table jubiting star (E-ADM) 12mg/m2, Changchun new alkali (VCR) 0.4 mg/m2, dissolved in physiological saline 500ml, continuous static drop 2 4h, 1st to 4th
-
NerLYNX nunini approved for extended assisted treatment for HER2-positive breast cancer patients
Time of Update: 2020-05-29
CANbridge Pharmaceuticals announced that its tyrosine kinase inhibitor NERLYNX (Neratinib) has been approved by the National Drug Administration (NMPA) for extended complementary treatment for adul
-
Stocktaking: Lancet Research Selection sq., May 16, 2020
Time of Update: 2020-05-29
Reedsiwe treatment of severe 2019 new coronary pneumonia effect is not significant https://doi.org/10.1016/ S0140-6736 (20) 31022-9 currently, there is no effective 2019 new coronary pneumonia t
-
First-line immunotherapy for lung cancer! BMS star immune combination Opdivo-Yervoy is approved by the U.S. FDA for the fifth indication to treat metastatic non-small cell lung cancer patients!
Time of Update: 2020-05-29
The U.S Food and Drug Administration (FDA) has approved the use of Odivo (Navuliu monoantigen, 3 mg / kg) in combination with Epiwood monoantigen (1 mg / kg, intravenous lygative) for first-line tr
-
Johnson and Johnson's CAR-T therapy JNJ-4528 for multiple myeloma: 86% of patients receive full remission
Time of Update: 2020-05-29
Johnson and Johnson released the latest results from its mid-stage trial of THE CAR-T cell therapy JNJ-4528, which showed a high response rate in patients with recurrent or refractory multiple myel
